H
Hedy L. Kindler
Researcher at University of Chicago
Publications - 433
Citations - 25609
Hedy L. Kindler is an academic researcher from University of Chicago. The author has contributed to research in topics: Mesothelioma & Cancer. The author has an hindex of 69, co-authored 406 publications receiving 20219 citations. Previous affiliations of Hedy L. Kindler include University of California, San Francisco & Duke University.
Papers
More filters
Journal ArticleDOI
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.
Peter Goldstraw,Kari Chansky,John Crowley,Ramón Rami-Porta,Hisao Asamura,Wilfried Ernst Erich Eberhardt,Andrew G. Nicholson,Patti A. Groome,Alan Mitchell,Vanessa Bolejack,David Ball,David G. Beer,Ricardo Beyruti,Frank C. Detterbeck,Wilfried Eberhardt,John G. Edwards,Françoise Galateau-Salle,Dorothy Giroux,Fergus V. Gleeson,James Huang,Catherine Kennedy,Jhingook Kim,Young Tae Kim,Laura Kingsbury,Haruhiko Kondo,Mark Krasnik,Kaoru Kubota,Antoon Lerut,Gustavo Lyons,Mirella Marino,Edith M. Marom,Jan P. van Meerbeeck,Takashi Nakano,Anna K. Nowak,Michael D Peake,Thomas W. Rice,Kenneth E. Rosenzweig,Enrico Ruffini,Valerie W. Rusch,Nagahiro Saijo,Paul Van Schil,Jean-Paul Sculier,Lynn Shemanski,Kelly G. Stratton,Kenji Suzuki,Yuji Tachimori,Charles F. Thomas,William D. Travis,Ming-Sound Tsao,Andrew T. Turrisi,Johan Vansteenkiste,Hirokazu Watanabe,Yi-Long Wu,Paul Baas,Jeremy J. Erasmus,Seiki Hasegawa,Kouki Inai,Kemp H. Kernstine,Hedy L. Kindler,Lee M. Krug,Kristiaan Nackaerts,Harvey I. Pass,David C. Rice,Conrad Falkson,Pier Luigi Filosso,Giuseppe Giaccone,Kazuya Kondo,Marco Lucchi,Meinoshin Okumura,Eugene H. Blackstone,F. Abad Cavaco,E. Ansótegui Barrera,J. Abal Arca,I. Parente Lamelas,A. Arnau Obrer,R. Guijarro Jorge,D. Ball,G.K. Bascom,A. I. Blanco Orozco,M. A. González Castro,M.G. Blum,D. Chimondeguy,V. Cvijanovic,S. Defranchi,B. de Olaiz Navarro,I. Escobar Campuzano,I. Macía Vidueira,E. Fernández Araujo,F. Andreo García,Kwun M. Fong,G. Francisco Corral,S. Cerezo González,J. Freixinet Gilart,L. García Arangüena,S. García Barajas,P. Girard,Tuncay Göksel,M. T. González Budiño,G. González Casaurrán,J. A. Gullón Blanco,J. Hernández Hernández,H. Hernández Rodríguez,J. Herrero Collantes,M. Iglesias Heras,J. M. Izquierdo Elena,Erik Jakobsen,S. Kostas,P. León Atance,A. Núñez Ares,M. Liao,M. Losanovscky,G. Lyons,R. Magaroles,L. De Esteban Júlvez,M. Mariñán Gorospe,Brian C. McCaughan,Catherine J. Kennedy,R. Melchor Íñiguez,L. Miravet Sorribes,S. Naranjo Gozalo,C. Álvarez de Arriba,M. Núñez Delgado,J. Padilla Alarcón,J. C. Peñalver Cuesta,Jongsun Park,H. Pass,M. J. Pavón Fernández,Mara Rosenberg,Enrico Ruffini,V. Rusch,J. Sánchez de Cos Escuín,A. Saura Vinuesa,M. Serra Mitjans,Trond Eirik Strand,Dragan Subotic,S.G. Swisher,Ricardo Mingarini Terra,Charles R. Thomas,Kurt G. Tournoy,P. Van Schil,M. Velasquez,Y.L. Wu,K. Yokoi +142 more
TL;DR: The methods used to evaluate the resultant Stage groupings and the proposals put forward for the 8th edition of the TNM Classification for lung cancer due to be published late 2016 are described.
Journal ArticleDOI
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan,Pascal Hammel,Michele Reni,Eric Van Cutsem,Teresa Macarulla,Michael J. Hall,Joon Oh Park,Daniel Hochhauser,Dirk Arnold,Do Youn Oh,Anke Reinacher-Schick,Giampaolo Tortora,Giampaolo Tortora,Hana Algül,Eileen M. O'Reilly,David McGuinness,Karen Y. Cui,Katia Schlienger,Gershon Y. Locker,Hedy L. Kindler +19 more
TL;DR: Among patients with a germline BRCA mutation and metastatic pancreatic cancer, progression-free survival was longer with maintenance olaparib than with placebo, and there was no significant between-group difference in health-related quality of life.
Journal ArticleDOI
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Aurélien Marabelle,Marwan Fakih,Juanita Lopez,Manisha H. Shah,Ronnie Shapira-Frommer,Kazuhiko Nakagawa,Hyun Cheol Chung,Hedy L. Kindler,Jose A. Lopez-Martin,Wilson H. Miller,Antoine Italiano,Steven Kao,Sarina Anne Piha-Paul,Jean Pierre Delord,Robert R. McWilliams,David Fabrizio,Deepti Aurora-Garg,Lei Xu,F. Jin,Kevin Norwood,Yung-Jue Bang +20 more
TL;DR: The association of high tissue TMB (tTMB-high) with outcomes in ten tumour-type-specific cohorts from the phase 2 KEYNOTE-158 study, which assessed the anti-PD-1 monoclonal antibody pembrolizumab in patients with selected, previously treated, advanced solid tumours, was prospectively explored.
Journal ArticleDOI
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
Hedy L. Kindler,Donna Niedzwiecki,Donna Hollis,Susan Sutherland,Deborah Schrag,Herbert Hurwitz,Federico Innocenti,Mary F. Mulcahy,Eileen M. O'Reilly,Timothy F. Wozniak,Joel Picus,Pankaj Bhargava,Robert J. Mayer,Richard L. Schilsky,Richard M. Goldberg +14 more
TL;DR: The addition of bevacizumab to gemcitabine does not improve survival in advanced pancreatic cancer patients, and the only statistically significant differences in grades 3 and 4 toxicity occurred for hypertension and proteinuria.
Journal ArticleDOI
Phase II Trial of Bevacizumab Plus Gemcitabine in Patients With Advanced Pancreatic Cancer
Hedy L. Kindler,Gregory Friberg,D. A. Singh,Gershon Y. Locker,Sreenivasa Nattam,Mark Kozloff,David A. Taber,Theodore Karrison,Abraham H. Dachman,Walter M. Stadler,Everett E. Vokes +10 more
TL;DR: The combination of bevacizumab plus gemcitabine is active in advanced pancreatic cancer patients, and the response rate and overall survival of patients who received gem citabine with the recombinant humanized anti-VEGF monoclonal antibody was assessed.